Ardent Capital Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Ardent Capital Management’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-923,463	Closed	-$1.71M	–	32
2023 Q1	$1.71M	Buy	+923,463	New	+$1.14M	1.23%	12

Other funds holding JNCE

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Ardent Capital Management's JNCE Position: Q2 2023 in Review

Ardent Capital Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 923,463 shares — an estimated $1.71M sold.

Ardent Capital Management first reported a position in JNCE in Q1 2023 and held it in 1 quarter. The position peaked at $1.71M in Q1 2023. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

Ardent Capital Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Ardent Capital Management sold 923,463 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $1.71M.
Ardent Capital Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
Ardent Capital Management's Jounce Therapeutics, Inc. Common Stock position peaked at $1.71M in Q1 2023.
1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Ardent Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.